Alembic Pharma shares gain after drugmaker gets USFDA approval for cancer treatment drug
Alembic Pharmaceuticals Ltd. on Thursday, April 16, said it has received final approval from the US Food and Drug Administration (USFDA) for its generic version of Methotrexate Injection. The stock gained in response to the news. The approval covers Methotrexate Injection USP, 50 mg/2 mL (multi-dose vials) and 1g/40 mL (single-dose vials), the company said…
